ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT)
CUSIP: 77313F106
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 109,265,652
- Total 13F shares
- 91,177,178
- Share change
- -5,128,328
- Total reported value
- $320,058,369
- Price per share
- $3.51
- Number of holders
- 182
- Value change
- -$17,903,454
- Number of buys
- 87
- Number of sells
- 89
Quarterly Holders Quick Answers
What is CUSIP 77313F106?
CUSIP 77313F106 identifies RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 77313F106:
Top shareholders of RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
3/4/5
13F
|
Director, Other*, 10%+ Owner · Company |
—
mixed-class rows
|
21,763,079
mixed-class rows
|
$100,686,510 | — | 19 Sep 2025 | |
| Roderick Wong |
3/4/5
|
Director, 10%+ Owner |
17%
|
18,236,124
|
$44,689,444 | — | 18 Jun 2025 | |
| MAVERICK CAPITAL LTD |
13F
13D/G
|
Company |
2.3%
from 13D/G
|
8,468,344
|
$27,606,801 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.5%
|
7,114,371
|
$23,192,850 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.3%
|
6,892,204
|
$22,468,585 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
3.6%
|
3,903,381
|
$12,725,022 | — | 30 Sep 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.5%
|
3,843,333
|
$12,529,266 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
3.3%
|
3,647,039
|
$11,889,347 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.3%
|
3,570,391
|
$11,639,475 | — | 30 Sep 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
2.6%
|
2,892,261
|
$9,428,771 | — | 30 Sep 2025 | |
| Newtyn Management, LLC |
13F
|
Company |
2.3%
|
2,502,863
|
$8,159,333 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
— |
0.9%
|
1,004,476
|
$7,895,181 | -$48,317,346 | 30 May 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
2,189,750
|
$7,138,585 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.9%
|
2,097,033
|
$6,836,329 | — | 30 Sep 2025 | |
| Kinnari Patel |
3/4/5
|
President, Head of R&D and Chief Operating Officer |
—
mixed-class rows
|
745,842
mixed-class rows
|
$6,417,297 | -$14,142 | 20 May 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,914,554
|
$6,242,766 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.6%
|
1,795,751
|
$5,854,148 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
1,745,310
|
$5,689,711 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
1,983,716
mixed-class rows
|
$5,458,482 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.5%
|
1,609,682
|
$5,247,563 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.2%
|
1,313,737
|
$4,282,783 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,271,093
|
$4,143,763 | — | 30 Sep 2025 | |
| Prosight Management, LP |
13F
|
Company |
1.2%
|
1,267,965
|
$4,133,566 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.97%
|
1,061,295
|
$3,461,000 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.93%
|
1,014,358
|
$3,306,807 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.8%
|
873,247
|
$2,846,787 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.78%
|
850,000
|
$2,771,000 | — | 30 Sep 2025 | |
| Jonathan David Schwartz |
3/4/5
|
Chief Science & Gene Therapy Officer |
—
mixed-class rows
|
418,746
mixed-class rows
|
$2,692,124 | -$64,338 | 18 Nov 2025 | |
| Gotham Makker |
3/4/5
|
Director |
—
mixed-class rows
|
1,037,149
mixed-class rows
|
$2,545,450 | — | 18 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.68%
|
744,074
|
$2,425,681 | — | 30 Sep 2025 | |
| Aaron Ondrey |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
262,815
mixed-class rows
|
$2,394,410 | -$4,257 | 03 Jul 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
657,013
|
$2,141,863 | — | 30 Sep 2025 | |
| Walleye Capital LLC |
13F
|
Company |
—
mixed-class rows
|
1,219,164
mixed-class rows
|
$2,062,508 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.57%
|
627,567
|
$2,045,868 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.53%
|
575,800
|
$1,877,108 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.51%
|
555,823
|
$1,812,003 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
534,266
mixed-class rows
|
$1,737,604 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.47%
|
514,921
|
$1,678,643 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.44%
|
484,481
|
$1,579,408 | — | 30 Sep 2025 | |
| Mark Andrew White |
3/4/5
|
General Manager, Commercial Affairs |
—
mixed-class rows
|
101,867
mixed-class rows
|
$1,560,177 | — | 31 Oct 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.4%
|
438,379
|
$1,429,116 | — | 30 Sep 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.4%
|
434,409
|
$1,416,173 | — | 30 Sep 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.4%
|
432,760
|
$1,410,798 | — | 30 Sep 2025 | |
| M28 Capital Management LP |
13F
|
Company |
0.35%
|
385,680
|
$1,257,317 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.35%
|
377,584
|
$1,230,924 | — | 30 Sep 2025 | |
| Carlos Garcia-Parada |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
71,328
mixed-class rows
|
$1,068,080 | — | 14 Feb 2022 | |
| FMR LLC |
13F
|
Company |
0.29%
|
311,701
|
$1,016,147 | — | 30 Sep 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.28%
|
305,438
|
$995,728 | — | 30 Sep 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.27%
|
300,000
|
$978,000 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.26%
|
280,708
|
$915,000 | — | 30 Sep 2025 |
Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) as of Q4 2025
As of 31 Dec 2025,
ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) was held by
182 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
91,177,178 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, VANGUARD GROUP INC, BlackRock, Inc., CITIGROUP INC, MORGAN STANLEY, SUVRETTA CAPITAL MANAGEMENT, LLC, Monaco Asset Management SAM, Newtyn Management, LLC, D. E. Shaw & Co., Inc., and MAVERICK CAPITAL LTD.
This page lists
182
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
171
Q4 2025 holders
182
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.